The present proposal envisages the development of potent, isoform-selective small-molecule nonmuscle myosin II-inhibitors, based on the ‘confirmed hit’ blebbistatin. Such molecules have the potential to become highly valuable tools in the study of cell motility and malignant disease, and serve as leads for targeted anti-invasive pharmacotherapeutics with lowered resistance susceptibility.